Literature DB >> 3299747

Gene for M1 subunit of ribonucleotide reductase is amplified in hydroxyurea-resistant hamster cells.

J M Cocking, P N Tonin, N M Stokoe, E J Wensing, W H Lewis, P R Srinivasan.   

Abstract

The hydroxyurea-resistant Chinese hamster cell line 600H has been shown to have greatly elevated quantities of ribonucleotide reductase. This increase in enzyme activity is due to an increased level of both the M1 and M2 subunit activities. The M1 subunit has been purified from the 600H cell line and shown to consist of a series of six protein spots with apparent molecular weights of 88,000 daltons, but with varying isoelectric points in the range of pH 6.5-7.0. Western blot analyses with antisera against the M1 and M2 proteins indicated that both subunit proteins are present in elevated quantities in the 600H cell line when compared to the wild-type V79 cell line. Southern blot analyses with genomic DNA from the series of stepwise-selected hydroxyurea-resistant cell lines leading to 600H showed that, in latter steps of selection, genomic sequences homologous to a mouse M1 cDNA have undergone a fivefold amplification. This was accompanied by a four- to eightfold increase in the single M1 homologous mRNA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3299747     DOI: 10.1007/BF01535204

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN: 0740-7750


  2 in total

1.  A docking model of human ribonucleotide reductase with flavin and phenosafranine.

Authors:  Panneerselvam Lakshmi Priya; Piramanayagam Shanmughavel
Journal:  Bioinformation       Date:  2009-09-30

2.  A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.

Authors:  William R Schelman; Sherry Morgan-Meadows; Rebecca Marnocha; Fred Lee; Jens Eickhoff; Wei Huang; Marcia Pomplun; Zhisheng Jiang; Dona Alberti; Jill M Kolesar; Percy Ivy; George Wilding; Anne M Traynor
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-13       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.